Type 1 Diabetes Market Report and Forecast 2024-2032

Type 1 Diabetes Market Report and Forecast 2024-2032


Type 1 Diabetes Market Report and Forecast 2024-2032

Type 1 Diabetes Market Outlook

The Type 1 diabetes market size was valued at USD 7.9 billion in 2023, driven increasing prevalence of Type 1 diabetes across the major markets. The market size is anticipated to grow at a CAGR of 6.8% during the forecast period of 2024-2032 to achieve a value of USD 15.3 billion by 2032.

Type 1 Diabetes: Introduction

Type 1 diabetes is an autoimmune condition where the pancreas produces little or no insulin, a hormone crucial for regulating blood sugar. It typically manifests in childhood or young adulthood but can appear at any age. The immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Management involves lifelong insulin therapy, diet monitoring, and blood sugar level checks to prevent complications and maintain overall health.

Key Trends in the Type 1 Diabetes Market

There's a notable trend towards more sophisticated insulin delivery systems, including insulin pumps and continuous glucose monitoring (CGM) systems. These technologies provide patients with more control over their condition and improve their quality of life. Smart insulin pens that track dosage and timing are also gaining popularity.

Healthcare providers and companies are increasingly focusing on integrated care solutions that combine medication, monitoring, and lifestyle management. There's a growing emphasis on comprehensive diabetes management programs that include educational support, nutritional planning, and mental health services.

The development and approval of artificial pancreas systems represent a significant advancement. These systems automate insulin delivery based on real-time glucose readings, closely mimicking the function of a healthy pancreas. This technology is continuously evolving, with improvements aimed at enhancing user convenience and accuracy.

There's an increasing investment in regenerative medicine research, focusing on ways to protect, regenerate, or replace the insulin-producing beta cells in the pancreas. Clinical trials involving stem cell therapies and immunotherapies are underway, aiming to halt or reverse the autoimmune attack on pancreatic cells.

The adoption of telemedicine and digital health platforms has accelerated, particularly intensified by the global pandemic. These platforms offer remote monitoring, and consultation capabilities, making diabetes management more accessible and efficient.

The trend towards personalized medicine is evident in the type 1 diabetes market, with a focus on tailoring treatment plans based on an individual's genetic makeup, lifestyle, and specific health needs. This approach aims to optimize treatment efficacy and reduce the risk of complications.

There's a trend towards greater collaboration between healthcare providers, patients, and industry players to improve outcomes. Patient-centric initiatives and support groups are increasingly important, providing individuals with the resources and community support needed to manage their condition effectively.

Type 1 Diabetes Market Segmentation

Market Breakup by Insulin Analog
  • Rapid-Acting Insulin
  • Short-Acting Insulin
  • Long-Acting Insulin
Market Breakup by Mode of Product Type
  • Injections/IV
  • Inhaled insulin
Market Breakup by Route of Administration
  • Parenteral (Subcutaneous, Intravenous)
  • Oral
Market Breakup by End User
  • Hospital
  • Research Institutes
  • Home Care
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Type 1 Diabetes Market Overview

In North America, the Type 1 diabetes market is characterized by a high prevalence of the condition, particularly in the United States and Canada. Factors such as increased awareness, better healthcare infrastructure, and a strong focus on research and innovation drive the market. The region witnesses significant investment in diabetes management technologies, including insulin pumps and continuous glucose monitoring systems. There's also a growing emphasis on personalized medicine and advanced treatment options, reflecting a trend towards improving the quality of life for individuals with Type 1 diabetes.

The European Type 1 diabetes market is marked by robust healthcare systems and widespread access to treatment. Countries like Germany, the UK, and France lead in terms of patient care and diabetes research. There is a strong focus on preventive care and early diagnosis, facilitated by public health initiatives and education campaigns. European regulatory policies support innovation in diabetic care technologies, fostering collaborations between academic institutions and the pharmaceutical industry. Additionally, the prevalence of lifestyle-related diseases and an aging population contribute to the market dynamics in the region.

Japan's market for Type 1 diabetes is influenced by a sophisticated healthcare system and high standards for patient care. The country is known for its technological advancements and integration of digital tools in healthcare. This includes the adoption of novel insulin delivery systems and glucose monitoring devices. There is a strong emphasis on research and development, with substantial government and private investment in finding innovative treatment solutions. Moreover, Japan's aging population and increasing awareness of diabetes as a national health concern are significant factors shaping the market landscape.

Type 1 Diabetes Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Eli Lilly
  • Pfizer
  • Stryker Corporation
  • Abbott Laboratories
  • DiaVasc, Inc.
  • Biodel, Inc.
  • Sanofi
  • Merck
  • Astellas Pharma
  • Mankind Corporation
  • Biodel, Inc,
  • Macrogenics
  • DiaVacs, Inc.
  • Novo Nordisk
  • Braun Melsungen
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Patient Profile
3.1 Patient Profile Overview
3.2 Patient Psychology and Emotional Impact Factors
3.3 Risk Assessment and Treatment Success Rate
4 Type 1 Diabetes Epidemiology Analysis – 7MM
4.1 7MM Epidemiology Scenario Overview (2017-2032)
4.2 United States Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3 EU-4 and United Kingdom Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3.1 Germany Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3.2 France Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3.3 Italy Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3.4 Spain Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3.5 United Kingdom Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.4 Japan Type 1 Diabetes Epidemiology Forecast (2017-2032)
5 Type 1 Diabetes Market Overview – 7MM
5.1 Type 1 Diabetes Market Historical Value (2017-2023)
5.2 Type 1 Diabetes Market Forecast Value (2024-2032)
6 Type 1 Diabetes Market Landscape – 7MM
6.1 Type 1 Diabetes: Developers Landscape
6.1.1 Analysis by Year of Establishment
6.1.2 Analysis by Company Size
6.1.3 Analysis by Region
6.2 Type 1 Diabetes: Product Landscape
6.2.1 Analysis by Type
7 Analysis by Technology Type 1 Diabetes Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Cost of Treatment
9 Type 1 Diabetes Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives, and Trends
9.7 Value Chain Analysis
10 Type 1 Diabetes Market Segmentation – 7MM
10.1 Type 1 Diabetes Market by Insulin Analog
10.1.1 Market Overview
10.1.2 Rapid-Acting Insulin
10.1.3 Short-Acting Insulin
10.1.4 Long-Acting Insulin
10.2 Type 1 Diabetes Market by Product Type
10.2.1 Market Overview
10.2.2 Injections/IV
10.2.3 Inhaled insulin
10.3 Type 1 Diabetes Market by Route of Administration
10.3.1 Market Overview
10.3.2 Parenteral (Subcutaneous, Intravenous)
10.3.3 Oral
10.4 Type 1 Diabetes Market by End User
10.4.1 Market Overview
10.4.2 Hospitals
10.4.3 Research Institutes
10.4.4 Home Care
10.5 Type 1 Diabetes Market by Region
10.5.1 Market Overview
10.5.2 United States
10.5.3 EU-4 and the United Kingdom
10.5.3.1 Germany
10.5.3.2 France
10.5.3.3 Italy
10.5.3.4 Spain
10.5.3.5 United Kingdom
10.5.4 Japan
11 United States Type 1 Diabetes Market
11.1 Type 1 Diabetes Market Historical Value (2017-2023)
11.2 Type 1 Diabetes Market Forecast Value (2024-2032)
11.3 Type 1 Diabetes Market by Disease Type
11.4 Type 1 Diabetes Market by Age group
12 EU-4 and United Kingdom Type 1 Diabetes Market
12.1 Type 1 Diabetes Market Historical Value (2017-2023)
12.2 Type 1 Diabetes Market Forecast Value (2024-2032)
12.3 Germany Type 1 Diabetes Market Overview
12.3.1 Type 1 Diabetes Market by Disease Type
12.3.2 Type 1 Diabetes Market by Age group
12.4 France Type 1 Diabetes Market Overview
12.4.1 Type 1 Diabetes Market by Disease Type
12.4.2 Type 1 Diabetes Market by Age group
12.5 Italy Type 1 Diabetes Market Overview
12.5.1 Type 1 Diabetes Market by Disease Type
12.5.2 Type 1 Diabetes Market by Age group
12.6 Spain Type 1 Diabetes Market Overview
12.6.1 Type 1 Diabetes Market by Disease Type
12.6.2 Type 1 Diabetes Market by Age group
12.7 United Kingdom Type 1 Diabetes Market Overview
12.7.1 Type 1 Diabetes Market by Disease Type
12.7.2 Type 1 Diabetes Market by Age group
13 Japan Type 1 Diabetes Market
13.1 Type 1 Diabetes Market Historical Value (2017-2023)
13.2 Type 1 Diabetes Market Forecast Value (2024-2032)
13.2.1 Type 1 Diabetes Market by Disease Type
13.2.2 Type 1 Diabetes Market by Age group
14 Regulatory Framework
14.1 Regulatory Overview
14.1.1 US FDA
14.1.2 EU EMA
14.1.3 INDIA CDSCO
14.1.4 JAPAN PMDA
14.1.5 Others
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding and Investment Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Eli Lilly
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisitions
20.1.5 Certifications
20.2 Pfizer
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisitions
20.2.5 Certifications
20.3 Stryker Corporation
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisitions
20.3.5 Certifications
20.4 Abbott Laboratories
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisitions
20.4.5 Certifications
20.5 DiaVasc, Inc.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisitions
20.5.5 Certifications
20.6 Biodel, Inc.
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisitions
20.6.5 Certifications
20.7 Sanofi
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisitions
20.7.5 Certifications
20.8 Merck
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisitions
20.8.5 Certifications
20.9 Astellas Pharma
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisitions
20.9.5 Certifications
20.10 Mankind Corporation
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisitions
20.10.5 Certifications
20.11 Biodel, Inc,
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisitions
20.11.5 Certifications
20.12 Macrogenics
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisitions
20.12.5 Certifications
20.13 DiaVacs, Inc.
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisitions
20.13.5 Certifications
20.14 Novo Nordisk
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisitions
20.14.5 Certifications
20.15 Braun Melsungen
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisitions
20.15.5 Certifications
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Company Competitiveness Analysis (Additional Insight)
22.1 Very Small Companies
22.2 Small Companies
22.3 Mid-Sized Companies
22.4 Large Companies
22.5 Very Large Companies
23 Payment Methods (Additional Insight)
23.1 Government Funded
23.2 Private Insurance
23.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings